Credit Suisse analyst Judah Frommer assumed coverage of Ultragenyx with an Outperform rating and $96 price target. The analyst made no changes to the firm’s prior rating, target price, or estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
- Ultragenyx to Present at the 2023 Barclays – Gene Editing & Gene Therapy Summit
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting